Context: Raised maternal body mass index (BMI) in association with hyperglycemia is associated with adverse pregnancy outcome. The contribution of raised BMI as an independent risk factor for adverse pregnancy outcome is of growing concern and increasing prevalence.
I
n the United States, obesity has a prevalence of 21% in prepregnant females (1) . Maternal obesity is associated with gestational diabetes mellitus (GDM) and adverse pregnancy outcomes, and it carries the highest risk for maternal mortality within the developed world (2) (3) (4) (5) . Most studies addressing the effects of maternal BMI on pregnancy outcomes include women with GDM (6, 7) . Two studies investigating maternal BMI in glucose-toler-ant women used World Health Organization (WHO) criteria to diagnose GDM (8, 9) . The International Association of Diabetes and Pregnancy Study Groups (IADPSG) recommend reducing the diagnostic glucose threshold for GDM using the 75-g oral glucose tolerance test (OGTT) as follows: fasting, Ͻ 5.1 mmol/liter; 1 h, Ͻ10.0 mmol/liter; and 2 h, Ͻ8.5 mmol/liter (10) . Therefore, many "glucosetolerant" women included in previous studies now satisfy diagnostic criteria for GDM. There are no published data investigating maternal BMI and pregnancy outcome in glucose-tolerant women using the IADPSG criteria.
This study addresses raised maternal BMI in the setting of glucose tolerance within the Atlantic Diabetes in Pregnancy (ATLANTIC-DIP) cohort, using updated IADPSG criteria (10) .
Subjects and Methods

Study design
ATLANTIC-DIP is a prospective observational study investigating universal screening for GDM across five antenatal centers in Ireland incorporating a population of 500,000. Data are collected from study entry until 12 wk postpartum.
A representative sample of our obstetric population including euthyroid women with normal glucose tolerance (IADPSG criteria) carrying singleton pregnancies was selected. Recruitment occurred from September 2006 to 2009. Normal glucose tolerance was based on IADPSG recommendations (10, 11) . Data were recorded using an optimized digital database, DIAMOND (Hicom, Woking, UK). Research ethics committee approval was obtained from participating centers, and recruitment occurred under informed consent.
Maternal BMI was calculated at booking visit (14 -24 wk), and OGTT (75 g) was performed at 24 -28 wk. WHO BMI categorization was used: normal, 18.5-25 kg/m 2 ; overweight, 25-29.9 kg/m 2 ; obese, Ͼ30 kg/m 2 (grade I, 30 -34.9 kg/m 2 ; grade II, 35-39.9 kg/m 2 ; grade III, Ͼ40 kg/m 2 ). Maternal outcomes included delivery mode [vaginal (normal vs. instrumental), lower segment cesarean section by Pfannensteil incision (LSCS) (elective and emergency)]; pregnancy-induced hypertension (PIH; blood pressure Ͼ140/90 mm Hg on at least two occasions more than 6 h apart in women with normal booking blood pressure); preeclamptic toxemia (PET) [hypertension, proteinuria (Ͼ300 mg/24 h) onset Ͼ20 wk]; antepartum hemorrhage (APH; vaginal bleeding from 24 wk until term); and postpartum hemorrhage (bleeding Ͼ500 ml after vaginal delivery, Ͼ1000 ml post-LSCS] (8).
Fetal outcomes included birthweight, congenital malformations (ICD-10), shoulder dystocia, neonatal hypoglycemia, jaundice, respiratory distress, miscarriage (death Ͻ20 wk gestation), stillbirth (death Ͼ24 wk gestation), and neonatal death (within 1 wk of delivery) (8) .
Statistical analysis
Maternal BMI was modeled as continuous and categorical variables to explain neonatal/fetal and maternal outcomes. Odds ratios were calculated using backward stepwise logistic regression, adjusted for age, parity, ethnicity, cigarette smoking, and venous glucose (PASW/SPSS 18.0; IBM, Chicago, IL). Covariates were selected based on previous data and using classification and regression tree (CRT) analysis (12, 13) . BMI "risk" cutoffs were calculated using CRT ( Fig. 1 ) with growth limits set at 0.05. Hypothesis testing was performed for multigroup comparisons using fixed-effects ANOVA and Tukey's post hoc comparison.
Data are expressed as means Ϯ SD, adjusted odds ratios, relative risk, and 95% confidence intervals. Statistical significance is accepted when the 95% confidence interval does not contain 1.0 (regression analyses) or zero (multigroup comparisons). The significance level (␣) was Ͻ0.05. Statistical assumptions were satisfied.
Results
Demographic factors
A total of 3656 women satisfied inclusion criteria. Mean maternal age was 31 Ϯ 5.3 yr (range, 16 -48) . A total of 3428 (94%) were Caucasian; 291 (8%) smoked during pregnancy; 1582 (43%) had normal BMI; and 1369 (38%) were overweight. A total of 695 (19%) were obese, 482 (13%) were grade I obese; 168 (5%) were grade II obese, and 55 (1.5%) were grade III obese (Supplemental Table 1 , published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org).
Effect of BMI on venous glucose
Maternal 
Effect of BMI on maternal blood pressure
Maternal BMI correlated with systolic blood pressure [r (1, 3191) ϭ 0.235; P Ͻ 0.001] and diastolic blood pressure [r (1, 3187) ϭ 0.166; P (two-tailed) Ͻ0.001].
Overweight and obese women had higher systolic blood pressure [ 
Maternal outcomes
Increasing maternal BMI showed higher odds for LSCS, PIH, and PET. There was no association between maternal BMI, antepartum hemorrhage, and postpartum hemorrhage.
Delivery mode
Elective LSCS was undertaken for 11.5% of overweight mothers and 18.5% of obese mothers, compared with 7.1% of mothers with normal BMI; 13.4% of overweight and 17.4% of obese mothers had emergency LSCS, compared with 10.6% of mothers with normal BMI. Emergency LSCS was most commonly undertaken consequent to failure of induction, labor progression, or instrumentation and fetal distress. Elective LSCS was most commonly undertaken due to abnormal fetal lie or prior history of emergency LSCS. Maternal glucose at 60 min was associated with emergency LSCS, but maternal glucose and elective LSCS were not associated ( Table 1) .
PIH occurred in 4.8% of normal BMI, 8.3% of overweight, and 17.8% of obese mothers and increased across obesity subcategories from 16.3-24.6% (Table 1) .
PET occurred in 2.9% of mothers with normal BMI and in 4.2% of overweight and 6.2% of obese mothers (Table 1) . Twenty-two percent of infants born to obese mothers and 16% born to overweight mothers were large for gestational age (LGA), compared with 12% born to mothers with normal BMI.
Fetal/neonatal outcomes
LGA birthweight was associated with fasting and 60-min glucose (Table 1) .
A total of 20.9% of infants born to overweight mothers and 27.3% born to obese mothers were macrosomic, compared with 15% of infants born to mothers with normal BMI. Fasting glucose was associated with macrosomia (Table 1) .
Congenital malformation
Two percent of infants born to obese mothers had a congenital malformation compared with 0.8% of infants born to mothers with normal BMI. Maternal glucose had no association. The main congenital malformations were talipes equinovarus, facial defects, and cardiovascular abnormality (Table 1) .
FIG. 1. Fitted logistic regression curves showing predicted probability plotted against BMI (in kg/ m
2 ) for each outcome measure: PET, PIH, emergency LSCS, elective LSCS, LGA birthweight, macrosomia, and congenital malformation 1. The vertical line represents the threshold BMI at which risk becomes statistically significant. RR, Relative risk with 95% confidence intervals.
There was no association between maternal BMI or glucose and neonatal hypoglycemia, jaundice, respiratory distress, neonatal intensive care unit admission, and fetal death. Figure 1 shows threshold BMI conferring increased risk for adverse outcome. CRT analyses showed greater association for adverse pregnancy outcome in primiparous women.
Discussion
We confirm the findings of previous analyses addressing independent effects of maternal BMI on adverse obstetric outcomes (8, 9) but with the application of stricter criteria for glucose tolerance (10, 11) . This is the first large study investigating maternal BMI and pregnancy outcomes in glucose-tolerant mothers using IADPSG criteria.
We show in this cohort that raised maternal BMI has the greatest independent association with the adverse pregnancy outcomes, LSCS (odds doubled per 12 kg/m 2 ), PIH (odds doubled per 14 kg/m 2 ), PET, LGA, and macrosomia. We also show an association with congenital malformation (odds doubled per 15 kg/m 2 ) independent of maternal glucose, suggesting a pathogenesis distinct from hyperglycemia.
ATLANTIC-DIP study 2 showed associations between raised maternal BMI and poor obstetric/neonatal outcome using WHO criteria for GDM (8) . We investigate a larger cohort (3656 vs. 2329 women) using IADPSG criteria for glucose tolerance and show that the risks for adverse obstetric outcome are similar, highlighting the greater risk conferred by raised maternal BMI over glucose in this cohort. We also show an exponential relationship between BMI and adverse pregnancy outcomes, reaching a threshold for unacceptable risk at 28 kg/m 2 . We use "booking BMI," calculated between 14 and 24 wk, as a surrogate indicator for pregestational BMI. Pregnancy-associated weight gain, sufficient to significantly alter BMI, should not have occurred across this gestational period (14, 15) . Clinically, our findings highlight the importance of optimizing maternal BMI below 28 kg/m 2 in the pre-and intergestational periods. This may best be achieved at the primary care level. We do not show significant association for maternal BMI and pregnancy loss. The rate of pregnancy loss was low. However, because this study was carried out in an obstetric setting, we cannot account for early pregnancy loss. Studies of women undergoing fertility treatment suggest that raised maternal BMI may contribute to early pregnancy loss (15) .
Although maternal glucose and BMI did not interact in terms of adverse effects, we do not rule out a pathogenic contribution of maternal insulin resistance. When you consider the correlation between maternal BMI, glucose, and blood pressure, our observations suggest that despite apparent glucose tolerance, many women of reproductive age with raised BMI have already developed an adverse metabolic milieu, unmasked during the physiological challenge of pregnancy. The correlation between birthweight, maternal BMI, and glucose further indirectly supports the presence of hyperinsulinemia in this cohort (16) . We propose routine universal screening for GDM (17, 18) and are also currently investigating hyperinsulinemia by performing OGTT and calculating homeostasis model of assessment for insulin resistance in women with BMI greater than 28 kg/m 2 at 32-34 wk. Long-term follow-up for the onset of type 2 diabetes mellitus is also merited in these women. Despite the best care, the odds for developing adverse pregnancy outcomes are greater in women with raised BMI at booking visit (6, 13, 19, 20) . Prepregnancy education, planning, and weight optimization are essential to modern obstetric and prepregnancy care (3-5). Large interventional studies are investigating lifestyle intervention and metformin ("EMPOWaR" Study) in "glucose-tolerant" pregnant women with raised BMI. Finally, we again highlight the obesity epidemic and its adverse consequences in a young female population.
